
    
      In this cohort study, the HBeAg positive chronic hepatitis B patients would be treated with
      peginterferon alpha 2a(PEG-IFN a-2a) for 96 week and followed 24 weeks after treatment. Serum
      HBV DNA load, HBsAg/anti-HBs level, HBeAg/anti-HBe will be tested at enrollment and every 3
      months during treatment and follow period. Parameters of liver and kidney function, and liver
      ultrasound examination will be tested with intervals 1-3 months. The rates of HBeAg
      seroconversion, HBsAg loss, and sustained viral response will be evaluated after treatment
      and follow up.
    
  